239 related articles for article (PubMed ID: 33142432)
21. [Q39 induces apoptosis in human leukemia cell line K562 in hypoxia].
Zhang B; Weng QJ; Chen ZT
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2007 May; 36(3):261-6. PubMed ID: 17571309
[TBL] [Abstract][Full Text] [Related]
22. Quinoxaline 1,4-dioxides: hypoxia-selective therapeutic agents.
Diab-Assef M; Haddadin MJ; Yared P; Assaad C; Gali-Muhtasib HU
Mol Carcinog; 2002 Apr; 33(4):198-205. PubMed ID: 11933073
[TBL] [Abstract][Full Text] [Related]
23. Effects of YC-1 on hypoxia-inducible factor 1 alpha in hypoxic human bladder transitional carcinoma cell line T24 cells.
Li Y; Zhao X; Tang H; Zhong Z; Zhang L; Xu R; Li S; Wang Y
Urol Int; 2012; 88(1):95-101. PubMed ID: 22041818
[TBL] [Abstract][Full Text] [Related]
24. Halting colorectal cancer metastasis via novel dual nanomolar MMP-9/MAO-A quinoxaline-based inhibitors; design, synthesis, and evaluation.
Ayoup MS; Abu-Serie MM; Awad LF; Teleb M; Ragab HM; Amer A
Eur J Med Chem; 2021 Oct; 222():113558. PubMed ID: 34116327
[TBL] [Abstract][Full Text] [Related]
25. Discovery of P3971 an orally efficacious novel anticancer agent targeting HIF-1α and STAT3 pathways.
Godse P; Kumar P; Yewalkar N; Deore V; Lohar M; Mundada R; Padgaonkar A; Manohar S; Joshi A; Bhatia D; Desai N; Damre A; Bhonde M; Joshi K; Sharma R; Kumar S
Anticancer Agents Med Chem; 2013 Nov; 13(9):1460-6. PubMed ID: 24102269
[TBL] [Abstract][Full Text] [Related]
26. Sulphonamido-quinoxalines: search for anticancer agent.
Ingle R; Marathe R; Magar D; Patel HM; Surana SJ
Eur J Med Chem; 2013 Jul; 65():168-86. PubMed ID: 23708011
[TBL] [Abstract][Full Text] [Related]
27. Quinoxaline 1,4-dioxides are novel angiogenesis inhibitors that potentiate antitumor effects of ionizing radiation.
Gali-Muhtasib H; Sidani M; Geara F; Mona AD; Al-Hmaira J; Haddadin MJ; Zaatari G
Int J Oncol; 2004 May; 24(5):1121-31. PubMed ID: 15067333
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and antimalarial activity of new 3-arylquinoxaline-2-carbonitrile derivatives.
Zarranz B; Jaso A; Aldana I; Monge A; Maurel S; Deharo E; Jullian V; Sauvain M
Arzneimittelforschung; 2005; 55(12):754-61. PubMed ID: 16430030
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and in vitro-anticancer and antimicrobial evaluation of some novel quinoxalines derived from 3-phenylquinoxaline-2(1H)-thione.
El-Hawash SA; Wahab AE
Arch Pharm (Weinheim); 2006 Aug; 339(8):437-47. PubMed ID: 16881038
[TBL] [Abstract][Full Text] [Related]
30. Novel Nicotinonitrile Derivatives Bearing Imino Moieties Enhance Apoptosis and Inhibit Tyrosine Kinase.
El-Hashash MA; El-Bordany EA; Marzouk MI; El-Naggar AM; Nawar TMS; El-Sayed WM
Anticancer Agents Med Chem; 2018; 18(11):1589-1598. PubMed ID: 29745342
[TBL] [Abstract][Full Text] [Related]
31. The novel hypoxic cytotoxin, TX-2098 has antitumor effect in pancreatic cancer; possible mechanism through inhibiting VEGF and hypoxia inducible factor-1α targeted gene expression.
Miyake K; Nishioka M; Imura S; Batmunkh E; Uto Y; Nagasawa H; Hori H; Shimada M
Exp Cell Res; 2012 Aug; 318(13):1554-63. PubMed ID: 22472348
[TBL] [Abstract][Full Text] [Related]
32. The inhibitory effect of hypoxic cytotoxin on the expansion of cancer stem cells in ovarian cancer.
Nozawa-Suzuki N; Nagasawa H; Ohnishi K; Morishige K
Biochem Biophys Res Commun; 2015 Feb; 457(4):706-11. PubMed ID: 25619133
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of N-substituted 3-oxo-1,2,3,4-tetrahydro-quinoxaline-6-carboxylic acid derivatives as tubulin polymerization inhibitors.
Qi J; Dong H; Huang J; Zhang S; Niu L; Zhang Y; Wang J
Eur J Med Chem; 2018 Jan; 143():8-20. PubMed ID: 29172084
[TBL] [Abstract][Full Text] [Related]
34. The discovery of novel, potent ERR-alpha inverse agonists for the treatment of triple negative breast cancer.
Du Y; Song L; Zhang L; Ling H; Zhang Y; Chen H; Qi H; Shi X; Li Q
Eur J Med Chem; 2017 Aug; 136():457-467. PubMed ID: 28525844
[TBL] [Abstract][Full Text] [Related]
35. New copper-based complexes with quinoxaline N1,N4-dioxide derivatives, potential antitumoral agents.
Urquiola C; Gambino D; Cabrera M; Lavaggi ML; Cerecetto H; González M; de Cerain AL; Monge A; Costa-Filho AJ; Torre MH
J Inorg Biochem; 2008 Jan; 102(1):119-26. PubMed ID: 17804074
[TBL] [Abstract][Full Text] [Related]
36. Novel hypoxia-targeting Pt(iv) prodrugs.
Xu Z; Zhao J; Gou S; Xu G
Chem Commun (Camb); 2017 Mar; 53(26):3749-3752. PubMed ID: 28303266
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and evaluation of the cytotoxic activity of novel ethyl 4-[4-(4-substitutedpiperidin-1-yl)]benzyl-phenylpyrrolo[1,2-a]quinoxaline-carboxylate derivatives in myeloid and lymphoid leukemia cell lines.
Desplat V; Vincenzi M; Lucas R; Moreau S; Savrimoutou S; Pinaud N; Lesbordes J; Peyrilles E; Marchivie M; Routier S; Sonnet P; Rossi F; Ronga L; Guillon J
Eur J Med Chem; 2016 May; 113():214-27. PubMed ID: 26945110
[TBL] [Abstract][Full Text] [Related]
38. Novel HIF-1α inhibitor CDMP-TQZ for cancer therapy.
Chu PC; Wu YC; Chen CY; Hung YS; Chang CS
Future Med Chem; 2021 Jun; 13(12):1057-1072. PubMed ID: 33896195
[No Abstract] [Full Text] [Related]
39. Synthesis of [1,2,4]triazolo[4,3-a]quinoxaline-1,3,4-oxadiazole derivatives as potent antiproliferative agents via a hybrid pharmacophore approach.
Kaneko D; Ninomiya M; Yoshikawa R; Ono Y; Sonawane AD; Tanaka K; Nishina A; Koketsu M
Bioorg Chem; 2020 Nov; 104():104293. PubMed ID: 33010622
[TBL] [Abstract][Full Text] [Related]
40. Ring-truncated deguelin derivatives as potent Hypoxia Inducible Factor-1α (HIF-1α) inhibitors.
Kim HS; Hong M; Lee SC; Lee HY; Suh YG; Oh DC; Seo JH; Choi H; Kim JY; Kim KW; Kim JH; Kim J; Kim YM; Park SJ; Park HJ; Lee J
Eur J Med Chem; 2015 Nov; 104():157-64. PubMed ID: 26457742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
